A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence suggests that combined inhibition of the androgen receptor (AR) and AKT may...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolinsky, M.P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., Michalarea, V., Riisnaes, R., Crespo, M., Figueiredo, I., Miranda, S., Nava Rodrigues, D., Flohr, P., Tunariu, N., Banerji, U., Ruddle, R., Sharp, A., Welti, J., Lambros, M., Carreira, S., Raynaud, F.I., Swales, K.E., Plymate, S., Luo, J., Tovey, H., Porta, N., Slade, R., Leonard, L., Hall, E., de Bono, J.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217345/
https://www.ncbi.nlm.nih.gov/pubmed/32205016
http://dx.doi.org/10.1016/j.annonc.2020.01.074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217345/
https://www.ncbi.nlm.nih.gov/pubmed/32205016
http://dx.doi.org/10.1016/j.annonc.2020.01.074

Ejemplares similares